ABSTRACT
OBJECTIVE: Analyze the applications and challenges of guidelines for pharmacoeconomic evaluation (PE) in China. METHODS: Reviewing what Chinese health policy need from pharmacoeconomics; analyzethe applications and challenges of guidelines for PE in China; summarize the application and development of the guidelines for PE in the world. RESULTS: PE plays an important role in Drug development, pricing, reimbursement and evidenc-based clinical pathway. Since PE guidelineis not mandatory in healthcare policy decision making in China, and there are lack of high-quality, reliable database for PE, the guideline encountered many difficulties and challenges in practice and hasn't play its due role yet. CONCLUSION: Based on the experience from other counties and practical in China, we recommended that PEguideline shouldbe mandatory. It is recommended to set up national research institutions for PE, and update or supplementthe guidelines regularly. Moreover, the basic research should be strengthened, such as rational drug use, pharmacoepidemiology, quality of life.